Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Int J Cardiol. 2019 Jan 15;275:77-82. doi: 10.1016/j.ijcard.2018.10.024. Epub 2018 Oct 11.
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease, associated with a number of cardiovascular diseases. We sought to investigate whether AS increases the risk of atrial fibrillation (AF) in a nationwide population-based study.
A total of 14,129 patients newly diagnosed with AS (mean age 41.8 ± 15.3 years, 72% male) were recruited from the Korean National Health Insurance Service database between 2010 and 2014 and followed up for new onset AF. Age- and sex-matched non-AS subjects (1:5, n = 70,645) were selected and compared with the AS patients.
During a mean follow-up of 3.5 years, AF was newly diagnosed in 486 patients (114 patients of the AS group). The AS patients developed AF more frequently than the non-AS subjects (2.32 vs. 1.51 per 1000 person-years). In multivariate Cox regression analysis, AS was an independent risk factor for AF (Hazard ratio [HR] 1.28, 95% confidence interval [1.03-1.58]). The AS with tumor necrosis factor inhibitor (TNFi) therapy group showed higher risk for AF (HR 1.60 [1.02-2.39]). In younger patients of the AS group (patients <40 years old), the risk for AF was three times higher than patients at same age in the non-AS group. AS was an independent risk factor for AF in men, but not in women (HR 1.53 [1.18-1.95]; HR 1.42 [0.94-2.08], respectively).
AS was an independent risk factor for AF, especially in those under 40 years of age and those administered TNFi. It would be reasonable to screen for AF and stroke prevention in these high-risk patients.
强直性脊柱炎(AS)是一种慢性炎症性风湿性疾病,与多种心血管疾病相关。我们旨在通过一项全国性基于人群的研究,探究 AS 是否会增加房颤(AF)的发病风险。
2010 年至 2014 年期间,我们从韩国国家健康保险服务数据库中招募了 14129 例新诊断为 AS(平均年龄 41.8±15.3 岁,72%为男性)的患者,并对新发 AF 进行随访。按年龄和性别匹配非 AS 对照组(1:5,n=70645),并与 AS 患者进行比较。
在平均 3.5 年的随访期间,486 例患者(AS 组 114 例)新诊断为 AF。AS 患者发生 AF 的频率高于非 AS 患者(每 1000 人年 2.32 例 vs. 1.51 例)。多因素 Cox 回归分析显示,AS 是 AF 的独立危险因素(风险比 [HR] 1.28,95%置信区间 [1.03-1.58])。AS 合并肿瘤坏死因子抑制剂(TNFi)治疗组发生 AF 的风险更高(HR 1.60 [1.02-2.39])。在 AS 组的年轻患者(年龄 <40 岁)中,AF 的发病风险是同年龄非 AS 组患者的三倍。AS 是男性发生 AF 的独立危险因素,但不是女性(HR 1.53 [1.18-1.95];HR 1.42 [0.94-2.08])。
AS 是 AF 的独立危险因素,尤其是在年龄<40 岁和接受 TNFi 治疗的患者中。对这些高危患者进行 AF 筛查和卒中预防是合理的。